This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
This day-long (FREE) seminar is a must-attend event for anyone in the pharmaceutical sector interested in understanding the “ins and outs” of doing business in the Territory, as well as an opportunity to interact with those who already have a keen understanding of doing business in Puerto Rico.
As Asia’s largest partnering event, it offers a comprehensive platform through its three main programs: exhibition, seminars, and partnering. Het bericht BioJapan 2024 verscheen eerst op ZoBio - Drug Discovery Technology. Jan Schultz attended One-on-One meetings to share insights about our.
As Asia’s largest partnering event, it offers a comprehensive platform through its three main programs: exhibition, seminars, and partnering. Het bericht BioJapan 2024 verscheen eerst op ZoBio - Drug Discovery Technology. Jan Schultz attended One-on-One meetings to share insights about our.
As Asia’s largest partnering event, it offers a comprehensive platform through its three main programs: exhibition, seminars, and partnering. Het bericht BioJapan 2024 verscheen eerst op ZoBio - Drug Discovery Technology. Jan Schultz will be attending One-on-One meetings to share insights.
Start Date End Date Event Event Type Organization 4/30/2024 4/30/2024 Seminar No. Start Date End Date Event Event Type Organization 4/30/2024 4/30/2024 Seminar No. Start Date End Date Event Event Type Organization 4/30/2024 4/30/2024 Seminar No. Start Date End Date Event Event Type Organization 4/30/2024 4/30/2024 Seminar No.
Ebrard said he hoped that trials would start between next month and January if they get approval from Mexico’s food and drug agency. He also said specifically that the Chinese companies were interested in producing a vaccine for Mexico and the rest of the Latin American market.
A recent editorial by Dean Brown in J Med Chem and follow-up posts by Keith Hornberger and Derek Lowe prompted me to think about how we train computational chemists and cheminformaticians for careers in drug discovery. When someone joins a drug discovery company from academia, they are often paired with more experienced colleagues.
My career choice was made from an early age when I was deeply affected by both my Uncle’s HIV+ diagnosis and then the extraordinary cocktails of antiretroviral drugs he took, which gave me another 20 years with him beyond his doctor’s initial grim projection. They are only going to do that when they feel valued and heard.
Zeese, 1955-2020 We are sad to report that the co-founder and President of Common Sense for Drug Policy, Kevin B. Kevin was one of the nation's foremost authorities on drug policy issues. He worked on a wide array of drug related issues since he graduated from George Washington University Law School in 1980. He is sorely missed.
In a recent traceability forum, the pharmaceutical industry and other trading partners were told to start testing their data systems now to ensure that any glitches are ironed out before prescription drug products must be electronically tracked through the supply chain to ward off counterfeiting. Source link.
1 In 2017, the US Food and Drug Administration (FDA) approved the first AAV-based gene replacement therapy (Luxturna), for Leber congenital amaurosis type 2. In this role, she works with leaders in the biotech and pharmaceutical industries to understand how Bio-Rad can accelerate drug discovery and development in new therapeutic areas.
Introducing Lias for a plenary at the event, Gutierrez said: “Courtney is in the paperwork for the seminar, she’s put down as the Acting Director. The rule has significant implications for the way that LDTs are regulated in general, but also has additional impact on the use of LDTs in the context of drug development (i.e.,
Start Date End Date Event Event Type Organization 2/28/2024 2/28/2024 Workshop on Medical Radioisotopes Conference ( CLOSED ) Belgian Council Presidency 2/28/2024 2/28/2024 The path to diagnosis – the challenge of rare diseases Webinar/ Seminar ( OPEN ) Martin Zeitz Center for Rare Diseases at the University Hospital Hamburg-Eppendorf 2/28/2024 (..)
Start Date End Date Event Event Type Organization 6/03/2024 6/03/2024 Product Management Service (PMS) Product UI and API training (access & navigation) Webinar/Seminar ( OPEN ) EMA 6/03/2024 6/07/2024 Mandatory use of ISO/ICH E2B(R3) individual case safety reporting in the E.U.:
She also once interned at Wenzhou Institute, University of Chinese Academy of Sciences and participated in the research of photocurable protein-based hydrogels for developing an in vitro liver model for hepatitis drug screening. Haiqi Chen Haiqi Chen is a graduate student from the Department of Biological Science at Columbia University.
This spring we’ve been quite fortunate to be joined by 6 Master’s students from Columbia University, who have been contributing to our creation of community resources as part of their Seminar in Biotechnology Course. Haiqi Chen Haiqi Chen is a graduate student from the Department of Biological Science at Columbia University.
Upcoming Webinar Hosted by Xtalks Webinar/Seminar ( OPEN) Xtalks 11/6/2023 11/6/2023 What is the evidence for high-risk medical devices in the field of cardiovascular disease and diabetes?
FDA fiscal year in review: New drug approvals in the wake of the pandemic and legislative reforms AgencyIQ analyzed CDER’s novel drug approvals in Fiscal Year 2023, identifying a recovery in approval numbers as the agency resumes a new normal following the pandemic. As a reminder, the U.S.
Start Date End Date Event Event Type Organization 8/5/2024 8/8/2024 PRAC August meeting Committee Meeting ( CLOSED ) Pharmacovigilance Risk Assessment Committee (PRAC) 8/6/2024 8/6/2024 Infectious Diseases Working Party Seminar ( CLOSED ) British In Vitro Diagnostics Association (BIVDA) 08/12/2024 5 weeks Explore innovative personalized therapeutic (..)
Seminars in Nephrology, 2015; 35(1): 2-11. Professor Peter Pickkers, M.D., I am excited to continue our collaboration with AM-Pharma for this trial.”. Nature Reviews Nephrology, 2011; 7(4): 209-217. and Chawla L.S. Nephron Clinical Practice, 2014; 127 (1-4): 30-34. 4 Chertow, G.M. 5 Alobaidi, R. 6 Hirsch, J.S. 2020.05.006. 7 Stevens, J.S.,
A January 2022 Seminars in Arthritis and Rheumatism publication noted that a “generic [drug] may only cost $1 million to $4 million and take two years to develop vs $100 million to $250 million and seven to eight years for a biosimilar.” Those studies lasted a median of 55 weeks (IQR: 46-78) and cost a median of $27.6 million). “We
December also has a huge number of legislative deadlines associated with the Food and Drug Omnibus Reform Act of 2022. Drug Importation: We may soon receive greater clarity about the FDA’s thinking about prescription drug importation plans. December also typically brings end-of-year perspectives on the agency’s accomplishments.
The European Commission also plans to create a Critical Medicines Alliance for a more coordinated effort in managing drug shortages within the E.U. We are expecting to see the release of an E.U. This effort will most likely be set up in early Q1 of 2024.
We are in New Orleans for the annual DRI Drug & Medical Device Seminar, so we would be remiss if we passed up the opportunity to write on a Louisiana case. The case will sound familiar. We reported six months ago on the dismissal of a case brought by the same plaintiff alleging that benzene in antiperspirant caused cancer.
DRI’s Drug and Medical Device Committee will hold its annual Seminar on May 3-5, 2023 , at the Hilton New Orleans Riverside, in New Orleans, Louisiana. The Seminar is a preeminent program for practitioners who represent pharmaceutical and medical device manufacturers.
First, there is no consumer protection claim because under Pennsylvania law, a prescription drug/device manufacturer does not have a duty to disclose information directly to consumers. Chief among them is that negligence is the sole theory of recovery for failure to warn in prescription drug/device cases in Pennsylvania.
In a prescription drug failure to warn case, that means plaintiff must demonstrate that a different warning would have changed whether the drug would have been prescribed to plaintiff or, in some circumstances, prescribed in the same way. It’s a don’t lose sight of the basics kind of post.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
59 
Let's personalize your content